Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck 4Q

Worldwide sales of Singulair were $1.3 billion in the quarter (+12%), and for the year sales were $4.7 billion (+7%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck 4Q

4Q Revenues: $10.1 billion (+67%)

4Q Earnings: $6.5 billion (earnings were $1.6 billion in 4Q08)

FY Revenues: $27.4 billion (+15%)

FY Earnings: $12.9 billion (+65%)

Comments: Worldwide sales of Singulair were $1.3 billion in the quarter (+12%), and for the year sales were $4.7 billion (+7%). Global sales of Zetia and Vytorin were $614 million and $577 million in the quarter, respectively, and for the year were $2.2 billion and $2.1 billion, respectively. The Merck/Schering-Plough partnership is now owned by Merck and the post-merger $399 million and $384 million in revenue from Zetia and Vytorin, respectively, are reflected in 4Q sales. Januvia sales were $558 million in the quarter (+35%), and for the year reached $1.9 billion. Janumet achieved sales of $202 million in the quarter (+69%) and $658 million for the year. Isentress sales were $234 million in the quarter (+80%), and for the year sales were $752 million (+108%).

Merck completed the acquisition of Schering-Plough on Nov. 3, 2009. Results for the quarter and the year include the results of legacy Schering-Plough operations. For the post-merger portion of the quarter, sales of Remicade were $431 million, Nasonex sales were $165 million, and sales of Clarinex were $101 million. Merger restructuring costs, primarily related to employee separations, were $1.5 billion for the quarter and $1.6 billion for the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters